Key facts
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 10 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Mar 2023, 15:30.
Robert E. Waltermire - 28 Feb 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Senior VP, Chief Pharma Dev.
- Issuer ticker
- MDGL
- Reported as of
- 28 Feb 2023
- Net transaction value
- -$1,853,238
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2023, 15:30:31 UTC
- Prior SEC filing
- 18 Jan 2023
- Next SEC filing
- 14 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian J. Lynch
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: -$1,853,238.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $439,600
- Shares
- +5,000
- Change %
- +88%
- Price
- $87.92
- Shares after
- 10,667
- Date
- 28 Feb 2023
- Ownership
- Direct
MDGL
transaction
Common Stock
Sale
- Transaction value
- $243,927
- Shares
- -900
- Change %
- -8.4%
- Price
- $271.03
- Shares after
- 9,767
- Date
- 28 Feb 2023
- Ownership
- Direct
- Footnotes
- F2
MDGL
transaction
Common Stock
Sale
- Transaction value
- $1,116,430
- Shares
- -4,100
- Change %
- -42%
- Price
- $272.30
- Shares after
- 5,667
- Date
- 28 Feb 2023
- Ownership
- Direct
- Footnotes
- F3
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $439,600
- Shares
- +5,000
- Change %
- +88%
- Price
- $87.92
- Shares after
- 10,667
- Date
- 01 Mar 2023
- Ownership
- Direct
MDGL
transaction
Common Stock
Sale
- Transaction value
- $527,192
- Shares
- -1,928
- Change %
- -18%
- Price
- $273.44
- Shares after
- 8,739
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F4
MDGL
transaction
Common Stock
Sale
- Transaction value
- $459,081
- Shares
- -1,672
- Change %
- -19%
- Price
- $274.57
- Shares after
- 7,067
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F5
MDGL
transaction
Common Stock
Sale
- Transaction value
- $358,189
- Shares
- -1,300
- Change %
- -18%
- Price
- $275.53
- Shares after
- 5,767
- Date
- 01 Mar 2023
- Ownership
- Direct
- Footnotes
- F6
MDGL
transaction
Common Stock
Sale
- Transaction value
- $27,619
- Shares
- -100
- Change %
- -1.7%
- Price
- $276.19
- Shares after
- 5,667
- Date
- 01 Mar 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 28 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $87.92
- Footnotes
- F1
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $87.92
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.06 to $274.99, inclusive.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.18 to $276.18, inclusive.
SEC remarks
As attorney-in-fact for Reporting Person